Drug intelligence / Profile preview

paracetamol + phenylephrine + pheniramine + ascorbic acid

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

This combination drug contains **paracetamol** (an analgesic and antipyretic that inhibits central prostaglandin synthesis to reduce pain and fever), **phenylephrine** (a sympathomimetic and alpha-adrenergic agonist acting as a nasal decongestant), **pheniramine** (an antihistamine that blocks H1 histamine receptors to relieve allergy symptoms such as sneezing, runny nose, and watery eyes), and **ascorbic acid** (vitamin C, an antioxidant included to compensate for increased needs during infection and to support immune function). The combination is formulated for the short-term treatment of symptoms associated with colds, influenza, and upper respiratory tract infections, such as headache, body aches, fever, nasal congestion, sneezing, and rhinorrhea[1][3][4][7].

Brand names
TherafluBIACOLDParmabic Hcl Tablets
Other names
Paracetamol, Phenylephrine, Pheniramine Maleate, Ascorbic Acid powder for oral solutionParacetamol, Ascorbic Acid, Phenylephrine Hydrochloride, Pheniramine Maleate Effervescent Tablets
02

Targets

HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)ADRA1A (α1A)

Beyond the preview

Go deeper on paracetamol + phenylephrine + pheniramine + ascorbic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + phenylephrine + pheniramine + ascorbic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call